Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Adicionar filtros








Intervalo de ano
1.
Clinical Psychopharmacology and Neuroscience ; : 446-449, 2019.
Artigo | WPRIM | ID: wpr-763546

RESUMO

Methylphenidate (MPH) is the most preferred drug for treatment of the attention deficit hyperactivity disorder (ADHD). Here, we aimed to discuss the possible effects and mechanisms of MPH on precocious puberty (PP) via a case series with seven children who had normal body mass index. In this case series we evaluated seven children with ADHD, who had received MPH for at least 6 months (0.5 mg/kg/dose three times a day, maximum 60 mg) and admitted to Department of Pediatric Endocrinology with PP symptoms. The mean age was 8.16 years. Basal hormonal levels (luteinizing hormone [LH], follicle stimulating hormone, and estrogen/testosterone) were within normal range. Results of LH-releasing hormone stimulation tests demonstrated central pubertal responses. Glutamine, dopamine and noradrenaline are most important excitatory neurotransmitters that have a role at the beginning of puberty. The effect of MPH, cumulating dopamine and noradrenaline in the synaptic gap could be associated with the acceleration of puberty with the excitatory effect of dopamine’s gonadotropin-releasing hormone (GnRH) release, excitatory effect of noradrenaline’s GnRH release and the disappearance of GnRH receptor expression suppressor effect on prolactin disinhibitory effect.


Assuntos
Adolescente , Criança , Humanos , Aceleração , Transtorno do Deficit de Atenção com Hiperatividade , Índice de Massa Corporal , Dopamina , Endocrinologia , Hormônio Foliculoestimulante , Glutamina , Hormônio Liberador de Gonadotropina , Metilfenidato , Neurotransmissores , Norepinefrina , Prolactina , Puberdade , Puberdade Precoce , Receptores LHRH , Valores de Referência
2.
Saudi Medical Journal. 2004; 25 (10): 1445-1448
em Inglês | IMEMR | ID: emr-68430

RESUMO

To investigate the possible association between Fc receptor [FcR] gamma polymorphisms and systemic lupus erythematosus [SLE]. We have investigated the full FcR gamma gene for polymorphisms using polymerase chain reaction [PCR]-single strand conformational polymorphism and DNA sequencing. The polymorphisms identified were genotype using PCR-restriction fragment length polymorphism. Systemic lupus erythematosus cases and controls were available from 3 ethnic groups: Turkish, Spanish and Caucasian. The study was conducted in the year 2001 at the Arthritis Research Campaign, Epidemiology Unit, Manchester University Medical School, Manchester, United Kingdom. Five single nucleotide polymorphisms were identified, 2 in the promoter, one in intron 4 and, 2 in the 3 UTR. Four of the 5 single nucleotide polymorphisms [SNPs] were relatively common and investigated in the 3 populations. Allele and genotype frequencies of all 4 investigated SNPs were not statistically different between cases and controls. Fc receptor gamma gene does not appear to contribute to SLE susceptibility. The identified polymorphisms may be useful in investigating other diseases where receptors containing the FcR gamma subunit contribute to the pathology


Assuntos
Receptores de IgG , Lúpus Eritematoso Sistêmico/imunologia , Polimorfismo Genético , Polimorfismo de Nucleotídeo Único , Reação em Cadeia da Polimerase , Receptores Fc/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA